Literature DB >> 17625374

Significance of gastrectomy as palliative surgery for gastric carcinoma with pyloric stenosis.

Satoshi Mizutani1, Takeshi Shioya, Kentaro Maejima, Masanori Yoshino, Osamu Komine, Hideki Bou, Masao Ogata, Masanori Watanabe, Tetsuo Shibuya, Akira Tokunaga, Takashi Tajiri.   

Abstract

We conducted a clinicopathological study of cases of gastric carcinoma with pyloric stenosis and examined treatment outcomes and the prognosis of cases of stage IV gastric carcinoma with pyloric stenosis and the validity of gastrectomy as palliative surgery in these cases. The outcomes of 49 surgeries for gastric carcinoma with pyloric stenosis were compared with those of 671 surgeries for gastric carcinoma without pyloric stenosis. The diagnosis of pyloric stenosis was confirmed with both upper gastrointestinal endoscopy and an upper gastrointestinal barium series. The frequency of pyloric stenosis in patients with gastric carcinoma was 7.3%. Serosal invasion was observed in about 70% of all cases. Of these cases, 53.1% were classified as stage IV. The resection rate was 73.5%, and the resection was classified as curative in 44.9% of cases. The incidence of complications after surgery in cases of stage IV gastric carcinoma was 47.1%. The median survival time was significantly greater in patients undergoing resection group than in those not undergoing resection (p=0.025). Most patients with gastric cancer and pyloric stenosis can be considered to have stage IV disease, which is associated with high rates of morbidity and mortality; thus, prevention of complications, and therefore, avoidance of gastrectomy is recommended in such patients. Nonetheless, in this study, gastrectomy was shown to improve prognoses in these patients.

Entities:  

Mesh:

Year:  2007        PMID: 17625374     DOI: 10.1272/jnms.74.241

Source DB:  PubMed          Journal:  J Nippon Med Sch        ISSN: 1345-4676            Impact factor:   0.920


  7 in total

Review 1.  A systematic review of surgery for non-curative gastric cancer.

Authors:  Alyson L Mahar; Natalie G Coburn; Simron Singh; Calvin Law; Lucy K Helyer
Journal:  Gastric Cancer       Date:  2011-10-28       Impact factor: 7.370

Review 2.  Non-curative gastric resection for patients with stage 4 gastric cancer--a single center experience and current review of literature.

Authors:  Yves Dittmar; Falk Rauchfuss; Max Goetz; Karin Jandt; Hubert Scheuerlein; Michael Heise; Utz Settmacher
Journal:  Langenbecks Arch Surg       Date:  2012-02-04       Impact factor: 3.445

3.  Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer.

Authors:  Alisa N Blumenthaler; Naruhiko Ikoma; Mariela Blum; Prajnan Das; Bruce D Minsky; Paul F Mansfield; Jaffer A Ajani; Brian D Badgwell
Journal:  J Surg Oncol       Date:  2020-08-18       Impact factor: 3.454

4.  [Advanced gastric cancer. Are there still indications for palliative surgical interventions?].

Authors:  I Gastinger; U Ebeling; L Meyer; F Meyer; U Schmidt; S Wolff; H Ptok; H Lippert
Journal:  Chirurg       Date:  2012-05       Impact factor: 0.955

5.  Effectiveness of laparoscopic stomach-partitioning gastrojejunostomy for patients with gastric outlet obstruction caused by advanced gastric cancer.

Authors:  Tsuyoshi Tanaka; Koichi Suda; Seiji Satoh; Yuichiro Kawamura; Kazuki Inaba; Yoshinori Ishida; Ichiro Uyama
Journal:  Surg Endosc       Date:  2016-06-10       Impact factor: 4.584

6.  Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis.

Authors:  Joseph Cowling; Bethany Gorman; Afrah Riaz; James R Bundred; Sivesh K Kamarajah; Richard P T Evans; Pritam Singh; Ewen A Griffiths
Journal:  J Gastrointest Cancer       Date:  2020-09-22

7.  Non-curative surgery for patients with gastric cancer with local peritoneal metastasis: A retrospective cohort study.

Authors:  Yuanqiang Dong; Shulan Ma; Shuo Yang; Fen Luo; Zhiming Wang; Fenghua Guo
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.